Cargando…

Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies

Primary hyperammonaemia is a term to describe an elevation of ammonia in blood or plasma due to a defect within the urea cycle, which is the pathway responsible for ammonia detoxification and arginine biosynthesis. Urea cycle disorders (UCDs) are rare diseases caused by genetic defects affecting any...

Descripción completa

Detalles Bibliográficos
Autor principal: Häberle, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518097/
https://www.ncbi.nlm.nih.gov/pubmed/33179600
http://dx.doi.org/10.34763/jmotherandchild.20202402si.2015.000006
_version_ 1784584151089807360
author Häberle, Johannes
author_facet Häberle, Johannes
author_sort Häberle, Johannes
collection PubMed
description Primary hyperammonaemia is a term to describe an elevation of ammonia in blood or plasma due to a defect within the urea cycle, which is the pathway responsible for ammonia detoxification and arginine biosynthesis. Urea cycle disorders (UCDs) are rare diseases caused by genetic defects affecting any of the six enzymes or two transporters that are directly involved in the urea cycle function. The clinical situation is variable and largely depends on the time of onset. Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death. Outside the neonatal period, symptoms are very unspecific but most often neurological (with wide variability), psychiatric and/or gastrointestinal. Early identification of patients is extremely important to start effective treatment modalities immediately. The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers. Long-term management of patients with UCDs consists of a low-protein diet, which needs to be balanced and supplemented to avoid deficiencies of essential amino acids, trace elements or vitamins and the use of nitrogen scavengers. The reader will find here a brief overview describing the most relevant aspects of the clinical management of UCDs in an attempt to raise awareness for this important group of rare diseases.
format Online
Article
Text
id pubmed-8518097
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-85180972021-11-23 Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies Häberle, Johannes J Mother Child Review Paper Primary hyperammonaemia is a term to describe an elevation of ammonia in blood or plasma due to a defect within the urea cycle, which is the pathway responsible for ammonia detoxification and arginine biosynthesis. Urea cycle disorders (UCDs) are rare diseases caused by genetic defects affecting any of the six enzymes or two transporters that are directly involved in the urea cycle function. The clinical situation is variable and largely depends on the time of onset. Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death. Outside the neonatal period, symptoms are very unspecific but most often neurological (with wide variability), psychiatric and/or gastrointestinal. Early identification of patients is extremely important to start effective treatment modalities immediately. The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers. Long-term management of patients with UCDs consists of a low-protein diet, which needs to be balanced and supplemented to avoid deficiencies of essential amino acids, trace elements or vitamins and the use of nitrogen scavengers. The reader will find here a brief overview describing the most relevant aspects of the clinical management of UCDs in an attempt to raise awareness for this important group of rare diseases. Sciendo 2020-10-02 /pmc/articles/PMC8518097/ /pubmed/33179600 http://dx.doi.org/10.34763/jmotherandchild.20202402si.2015.000006 Text en © 2020 Johannes Häberle, published by Sciendo https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Review Paper
Häberle, Johannes
Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies
title Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies
title_full Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies
title_fullStr Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies
title_full_unstemmed Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies
title_short Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies
title_sort primary hyperammonaemia: current diagnostic and therapeutic strategies
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518097/
https://www.ncbi.nlm.nih.gov/pubmed/33179600
http://dx.doi.org/10.34763/jmotherandchild.20202402si.2015.000006
work_keys_str_mv AT haberlejohannes primaryhyperammonaemiacurrentdiagnosticandtherapeuticstrategies